Sofinnova Partners Closes €82M MD Start IV MedTech Fund

Sofinnova Partners has closed its MD Start IV fund at €82 million, exceeding its original target in an oversubscribed raise, as EU-Startups reported.

The Paris-based venture firm will deploy the capital to build new MedTech startups. MD Start IV follows the strategy of Sofinnova's earlier MD Start vehicles, which create companies rather than back existing ones.

The oversubscription signals continued investor appetite for early-stage medical technology despite a tighter European funding environment. Limited partners committed beyond the fund's initial cap, pushing the final close to €82 million.

Sofinnova Partners has built its reputation on company creation in the life sciences. The MD Start program sits at the formation end of that strategy: the firm identifies unmet clinical needs, assembles founding teams, and launches startups around the resulting technology platforms.

For Europe's MedTech sector, the fund close adds a fresh pool of dedicated capital at the earliest and often hardest-to-finance stage. Company-creation funds of this type typically take startups from concept through first clinical and regulatory milestones, the point at which traditional venture investors begin to engage.

The next signal to watch will be the first wave of startups spun out of MD Start IV — and how quickly Sofinnova can move from a closed fund to launched companies.